U.S. INTRAVENOUS IMMUNOGLOBULIN MARKET ANALYSIS

U.S. Intravenous Immunoglobulin MarketSize and Trends

The U.S. intravenous immunoglobulin market is estimated to be valued at US$ 6.33 Bn in 2021, and is expected to exhibit a CAGR of 6.8% over the forecast period (2021-2028).

Figure 1: U.S. Intravenous Immunoglobulin Market Share (%) Analysis, By Formulation, 2021

The increasing cases of Kawasaki disease for which intravenous immunoglobulins are used as a treatment, is expected to drive growth of the market over the forecast period.

Figure 2: U.S. Intravenous Immunoglobulin Market Share (%) Analysis, By Application, 2021

Market Trends

Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19 as pandemic on March 11, 2020. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 234 million cases and 4.80 million deaths due to coronavirus (COVID-19) were reported till October 04, 2021, across the globe.

Impact of COVID-19 on Demand and Supply of Intravenous Immunoglobulin

The COVID-19 pandemic and lockdown in various countries across the globe have impacted the financial status of businesses across all sectors including private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. The COVID-19 pandemic has affected the economy of various regions across the globe in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) through its financial impact on companies and financial markets. Several countries such as Thailand, Indonesia, and Singapore are facing problems with regards to transportation and distribution of healthcare products.

However, impact of the coronavirus (COVID-19) pandemic is expected to drive the growth of the U.S. intravenous immunoglobulin market owing to increasing research and development activities of intravenous immunoglobulins (IVIG) for the treatment of COVID-19. For instance, according to the article published in Respiration journal, in January 2021, early IVIG administration was associated with reduced ventilator use, hospital and intensive care unit length of stay in a retrospective study conducted in the U.S. and Germany including patients from three hospitals.